Analogously, targeting CD43 resulted in down-modulation of CD43 in both CLL and Th cells, followed by selective reduction of surface galectin-1 and proliferation in CLL cells.24 This evidence concerns the gene LGALS1 and B-cell chronic lymphocytic leukemia.